Abstract: This disclosure relates to compounds of Formula IV: for fibrin imaging, wherein the compounds comprise an imaging or therapeutic radioisotope.

Abstract: The present disclosure relates to magnetic resonance imaging (MRI) using biochemically responsive imaging probes that can be used in, for example, non-invasive pH mapping in cancer and/or diseases characterized by aberrant metabolism using contrast enhanced MRI.

Abstract: Provided herein are therapeutic nanoparticles including a radiolabel, a chelator that is covalently linked to the therapeutic nanoparticle and to the radiolabel, and a nucleic acid molecule that is covalently linked to the therapeutic nanoparticle. The therapeutic nanoparticle has a diameter between about 10 nanometers (nm) to about 30 nm, and the therapeutic nanoparticle is magnetic. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject. Also provided herein are methods of detecting, diagnosing, and/or monitoring a metastatic cancer tissue in a subject. Also provided herein are methods of preparing these therapeutic nanoparticles.

Abstract: Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

Abstract: Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

Abstract: Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

Abstract: Disclosed herein are collagen-targeted imaging agents for positron emission tomography and related imaging methods using the collagen-targeted imaging agents. The collagen-targeted imaging agent is a cyclic polypeptide comprising a cyclic main body, wherein the cyclic main body comprises at least one S—S bond; at least two branches, wherein each of the at least two branches comprises at least three amino acids; and a linker, wherein the linker is capable of linking an imaging reporter.

Abstract: Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

Abstract: A system acquires MR imaging data of a portion of patient anatomy associated with proton spin lattice relaxation time in a rotating frame using an RF (Radio Frequency) signal generator configured to generate RF excitation pulses and a magnetic field gradient generator configured to generate anatomical volume select magnetic field gradients for phase encoding and readout RF data acquisition. The RF signal generator and the gradient generator are configured to provide a rotating frame preparation pulse sequence comprising at least one of, (a) a T1 spin lattice relaxation in a rotating frame (T1?) preparation pulse sequence of adiabatic pulses comprising modulated RF pulses and modulated magnetic field gradients for slice selection and (b) a T2 spin-spin relaxation in a rotating frame (T2?) preparation pulse sequence of adiabatic pulses comprising modulated RF pulses and modulated magnetic field gradients for slice selection.

Abstract: Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn2+ and Mn3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity MnIII-HBET is rapidly converted to high relaxivity MnII-HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

Abstract: Disclosed herein are collagen-targeted imaging agents for positron emission tomography and related imaging methods using the collagen-targeted imaging agents. The collagen-targeted imaging agent is a cyclic polypeptide comprising a cyclic main body, wherein the cyclic main body comprises at least one S—S bond; at least two branches, wherein each of the at least two branches comprises at least three amino acids; and a linker, wherein the linker is capable of linking an imaging reporter.

Abstract: This disclosure relates to compounds of formula (I) shown below: [formula (I)], or a pharmaceutically acceptable salt thereof. These compounds can be used as imaging probes, e.g., for diagnosis of fibrosis or fibrogenesis.

Abstract: A system and method performing a medical imaging process includes arranging a subject to receive an exogenously administered free radical probe, performing an Overhauser-enhanced MRI (OMRI) imaging process to acquire data from the subject, and reconstructing the data to generate a report indicating a spatial distribution of free radicals in the subject.

Abstract: Fibrin-specific imaging agents that contain at least two imaging reporters are described, as well as methods of making and using the contrast agents.

Abstract: Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn2+ and Mn3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity MnIII-HBET is rapidly converted to high relaxivity MnII-HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

Abstract: Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn2+ and Mn3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity MnIII-HBET is rapidly converted to high relaxivity MnII-HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

Abstract: A method for increasing the relaxivity of a contrast agent having a metal ion complexed to a chelator is disclosed. The metal ion complex is tethered to the remainder of the molecule by at least two points of attachment such that local motion is limited and higher relaxivity can be achieved. In one non-limiting example version of the invention, the alanine analogue of Gd(DOTA), Gd(DOTAla) wherein Gd is gadolinium and DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid was integrated into polypeptide structures. This resulted in very rigid attachment of the metal ion complex to the peptide backbone. Rigid molecular structures provide fewer degrees of rotational freedom, resulting in greater control over the rotational dynamics and resultant relaxivity. In the case of Gd(DOTAla), the metal complex is tethered to the peptide via the amino acid side chain to the DOTA moiety and via a dative bond from an amide oxygen to the Gd(III) ion.

Abstract: Fluorescent compounds include near infrared fluorochromes that are covalently linked to polyethylene glycol (PEG). The compounds behave like PEG in biological systems. One fluorescent compound has the formula (I): wherein R1 is a fluorescent moiety having an absorption wavelength maxima in the range of 450 to 1500 nanometers, R2 is a non-reactive moiety, and n is an integer. Another fluorescent compound has the formula (II): wherein R1 is a fluorescent moiety having an absorption wavelength maxima in the range of 450 to 1500 nanometers, R2 is a non-reactive moiety, R3 is a scaffold including an amino acid group, and n is an integer. The scaffold can be attached to a chelate, protein, enzyme, peptide, antibody, or drug that can target a site in a subject.

Abstract: In part, the invention relates to fiduciary markers suitable for affixing to a patient that are detectable with respect an imaging modality such as MRI and methods of making the same. The markers include a paramagnetic material disposed therein that generates a distinguishable signal relative to a patient or other biological sample of interest during an imaging data collection session. Further, the markers demonstrate desirable signal to noise ratios across two or more MRI data collection procedures in one embodiment. The length of the markers is also adjustable by, for example, cutting or tearing a substrate upon which a substantially fluid-free region straddles a specified separation position on the substrate.

Abstract: A system acquires MR imaging data of a portion of patient anatomy associated with proton spin lattice relaxation time in a rotating frame using an RF (Radio Frequency) signal generator configured to generate RF excitation pulses and a magnetic field gradient generator configured to generate anatomical volume select magnetic field gradients for phase encoding and readout RF data acquisition.